Co-localization of a CD1d-binding glycolipid with an adenovirus-based malaria vaccine for a potent adjuvant effect

Xiangming Li, Jing Huang, Akira Kawamura, Ryota Funakoshi, Steven A. Porcelli, Moriya Tsuji

Research output: Contribution to journalArticle

4 Scopus citations


A CD1d-binding, invariant (i) natural killer T (NKT)-cell stimulatory glycolipid, α-Galactosylceramide (αGalCer), has been shown to act as an adjuvant. We previously identified a fluorinated phenyl ring-modified αGalCer analog, 7DW8-5, displaying a higher binding affinity for CD1d molecule and more potent adjuvant activity than αGalCer. In the present study, 7DW8-5 co-administered intramuscularly (i.m.) with a recombinant adenovirus expressing a Plasmodium yoelii circumsporozoite protein (PyCSP), AdPyCS, has led to a co-localization of 7DW8-5 and a PyCSP in draining lymph nodes (dLNs), particularly in dendritic cells (DCs). This occurrence initiates a cascade of events, such as the recruitment of DCs to dLNs and their activation and maturation, and the enhancement of the ability of DCs to prime CD8+ T cells induced by AdPyCS and ultimately leading to a potent adjuvant effect and protection against malaria.

Original languageEnglish (US)
Pages (from-to)3171-3177
Number of pages7
Issue number24
StatePublished - May 31 2017



  • Adenovirus
  • CD1d
  • CD8+ T cells
  • Co-localization
  • Dendritic cells
  • Glycolipid adjuvant
  • Intramuscular injection
  • Lymph node
  • Malaria vaccine
  • Protection

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this